Description: Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Home Page: www.brainstorm-cell.com
1325 Avenue of Americas
New York,
NY
10019
United States
Phone:
201 488 0460
Officers
| Name | Title |
|---|---|
| Mr. Chaim Lebovits | President & CEO |
| Dr. Irit Arbel DSc, Ph.D. | Co-Founder & Independent Vice Chair of the Board |
| Ms. Alla Patlis CPA, M.B.A. | Interim CFO & Controller |
| Mr. Uri Yablonka | Executive VP, Chief Business Officer, Secretary & Director |
| Dr. Hartoun Hartounian Ph.D. | Executive VP & COO |
| Dr. Daniel Offen Ph.D. | Chief Scientific Advisor |
| Ms. Mary Kay Turner | Senior Vice President of Patient Advocacy & Government Affairs |
| Dr. Ibrahim Dagher M.D. | Executive VP & Chief Medical Officer |
| Dr. Netta Blondheim-Shraga Ph.D. | Senior Vice President of Research and Development |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 62.9149 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 29 |